Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 59 | 441 | 1,924 | 18,051 | 5,398 |
| Cost of Goods | N/A | -366 | 1,284 | 3,434 | 1,491 |
| Gross Profit | 59 | 807 | 640 | 14,617 | 3,907 |
| Operating Expenses | 72,984 | 68,953 | 28,275 | 52,491 | 86,532 |
| Operating Income | -72,925 | -68,512 | -27,351 | -37,440 | -82,134 |
| Interest Expense | 0 | 0 | 0 | 4,170 | 2,391 |
| Other Income | -5,169 | 33,497 | -4,179 | -20 | -20 |
| Pre-tax Income | -78,094 | -35,015 | -31,530 | -41,630 | -84,545 |
| Income Tax | 165 | 114 | 14 | 28 | -196 |
| Net Income Continuous | -78,259 | -35,129 | -31,544 | -41,658 | -84,349 |
| Net Income Discontinuous | N/A | N/A | N/A | N/A | -27 |
| Net Income | $-78,259 | $-35,129 | $-31,544 | $-41,658 | $-84,376 |
| EPS Basic Total Ops | -5.84 | -7.94 | -113.58 | -1,063.00 | -2,369.05 |
| EPS Basic Continuous Ops | -5.84 | -7.94 | -113.58 | -1,062.65 | -2,369.05 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | N/A | -0.77 |
| EPS Diluted Total Ops | -5.84 | -20.91 | -113.58 | -1,063.00 | -2,369.05 |
| EPS Diluted Continuous Ops | -5.84 | -4.69 | -113.58 | -1,062.65 | -2,369.05 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | N/A | -0.77 |
| EPS Diluted Before Non-Recurring Items | N/A | -20.91 | -114.00 | -1,054.76 | -2,372.38 |
| EBITDA(a) | $-72,581 | $-68,343 | $-21,458 | $-35,885 | $-79,683 |